(Total Views: 536)
Posted On: 10/08/2021 10:58:25 AM
Post# of 148905
NEW DELHI, Oct 8 (Reuters) - Merck & Co's (MRK.N) experimental antiviral drug molnupiravir has not shown "significant efficacy" against moderate COVID-19, a source with the Drug Controller General of India said.
Aurobindo Pharma Ltd wants to discontinue a late-stage trial of molnupiravir in moderate COVID-19 patients, the regulator's expert committee said on Friday.
https://www.reuters.com/business/healthcare-p...021-10-08/
Aurobindo Pharma Ltd wants to discontinue a late-stage trial of molnupiravir in moderate COVID-19 patients, the regulator's expert committee said on Friday.
https://www.reuters.com/business/healthcare-p...021-10-08/
(10)
(0)Scroll down for more posts ▼
